Osteoporosis Drugs Market by Product and Geography - Forecast and Analysis 2021-2025

The osteoporosis drugs market share is expected to increase by USD 5.11 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 9.64%.

This osteoporosis drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers osteoporosis drugs market segmentation by product (antiresorptive drugs and anabolic drugs) and geography (North America, Europe, Asia, and ROW). The osteoporosis drugs market report also offers information on several market vendors, including Amgen Inc., Asahi Kasei Corp., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., and UCB SA among others.

What will the Osteoporosis Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Osteoporosis Drugs Market Size for the Forecast Period and Other Important Statistics

 "As per the World Bank Group and the National Institutes of Health (NIH), the incidence of the geriatric population at a global level is expected to grow from 8.48% in 2016 to approximately 17% by 2050."

Osteoporosis Drugs Market: Key Drivers and Trends

The availability of guidelines for disease management is notably driving the osteoporosis drugs market growth, although factors such as high cost of treatment may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the osteoporosis drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Osteoporosis Drugs Market Driver

The available guidelines for disease management is one of the key drivers for the osteoporosis drug market share growth. It is a mandate for physicians to adopt evidence-based recommendations to their patients due to an increase in global incidences of osteoporosis. The guidelines for disease management are framed as per scientific evidence and adopted based on several factors such as the needs of patients and previous and ongoing therapies. Moreover, there is a number of international organizations developing models to ensure optimal delivery of recommended osteoporosis therapies in healthcare systems. Thus, the guidelines are expected to contribute to the osteoporosis drugs market growth during the forecast period.

Key Osteoporosis Drugs Market Challenge

The high costs of treatment is a key challenge for the growth of the osteoporosis drugs market vendors. Treatment goals are often to reduce pain and improve functions as no therapy has the potential to reverse joint damage, resulting in life-long expenses for treating diseases and preventing symptoms using drugs. Moreover, the cost of treatments differs across regions, depending on several health condition factors. According to the CDC, osteoporosis is the second most health condition treated globally. Thus, the imposition of a high financial burden on patients as well as healthcare systems is expected to hinder the osteoporosis drugs market growth during the forecast period.

This osteoporosis drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Market Overview

The parent market, the global pharmaceuticals market, covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. 

Who are the Major Osteoporosis Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Amgen Inc.
• Asahi Kasei Corp.
• Eli Lilly and Co.
• F. Hoffmann-La Roche Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Radius Health Inc.
• Teva Pharmaceutical Industries Ltd.
• UCB SA

 

This statistical study of the osteoporosis drugs market encompasses successful business strategies deployed by the key vendors. The osteoporosis drugs market is fragmented and the vendors are deploying growth strategies such as collaborations and adopting license agreements to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The osteoporosis drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Osteoporosis Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the osteoporosis drugs market in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia.

The increase in patient access for scheme reimbursements will facilitate the osteoporosis drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Product Segments in the Osteoporosis Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The osteoporosis drugs market share growth by the antiresorptive drugs segment will be significant during the forecast period. The high availability of antiresorptive drugs for treating the rising prevalence of osteoporosis is driving the growth of the market segment. These drugs are ideally used in patients with osteoporosis to increase their bone strength. Moreover, these drugs are most widely used as first-line antiresorptive as they have good safety profiles. Therefore, the easy availability and effective treatments are estimated to boost the osteoporosis drugs market through its antiresorptive segment during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the osteoporosis drugs market size and actionable market insights on post COVID-19 impact on each segment.

You may be interested in the regional reports:

BRIC Nations Osteoporosis Drugs market - The market share is expected to grow moderately and post a CAGR of over 17% during the forecast period.

APAC Osteoporosis Drugs market - The market share will grow at a CAGR of 4.73 percent over the period 2014-2019.

Osteoporosis Drugs Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 9.64%
Market growth 2021-2025	$ 5.11 billion
Market structure	Fragmented
YoY growth (%)	8.48
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 38%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Amgen Inc., Asahi Kasei Corp., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd., and UCB SA
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Osteoporosis Drugs Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive osteoporosis drugs market growth during the next five years
• Precise estimation of the osteoporosis drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the osteoporosis drugs industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of osteoporosis drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch